



COMPANY OVERVIEW

Oragenics, Inc. is focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established exclusive worldwide channel collaborations with Intrexon Corporation Inc., a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States.

RECENT NEWS

Oragenics, Inc. Receives Clearance to Enroll Patients in Germany and the United Kingdom into Its Phase 2 Clinical Trial of AG013 for Oral Mucositis

Nov 15 2018, 4:15 PM EST

STOCK OVERVIEW

Symbol	OGEN
Exchange	NYSE American
Market Cap	27.35m
Last Price	\$0.9293
52-Week Range	\$0.38 - \$4.712

INVESTOR RELATIONS

CORE IR
John Marco
Managing Director
T: 310-819-2948
johnm@coreir.com

MANAGEMENT TEAM

Alan Joslyn, Ph.D.

President and Chief Executive Officer

Michael Sullivan

Chief Financial Officer

Dr. Martin Handfield

Senior Vice President of Discovery Research

ORAGENICS, INC.

4902 Eisenhower Blvd.
Suite 125
Tampa, FL 33634
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.